{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:01:12Z","timestamp":1762866072333},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T00:00:00Z","timestamp":1475452800000},"content-version":"vor","delay-in-days":1459,"URL":"http:\/\/creativecommons.org\/licenses\/cc-by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1,1]]},"DOI":"10.1093\/cid\/cis859","type":"journal-article","created":{"date-parts":[[2012,10,6]],"date-time":"2012-10-06T06:17:03Z","timestamp":1349504223000},"page":"100-105","source":"Crossref","is-referenced-by-count":36,"title":["Close Monitoring of Hepatitis B Surface Antigen Levels Helps Classify Flares During Peginterferon Therapy and Predicts Treatment Response"],"prefix":"10.1093","volume":"56","author":[{"given":"Milan J.","family":"Sonneveld","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roeland","family":"Zoutendijk","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajo J.","family":"Flink","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louwerens","family":"Zwang","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology"},{"name":"Department of Biostatistics, Erasmus MC University Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry L. A.","family":"Janssen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,10,5]]},"reference":[{"key":"key\n\t\t\t\t20180912062312_CIS859C1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180912062312_CIS859C2","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180912062312_CIS859C3","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","article-title":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180912062312_CIS859C4","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/gast.2001.22461","article-title":"Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease","volume":"120","author":"Perrillo","year":"2001","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180912062312_CIS859C5","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1136\/gut.2004.062208","article-title":"Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy","volume":"54","author":"Flink","year":"2005","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180912062312_CIS859C6","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/jhep.2001.28459","article-title":"Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?","volume":"34","author":"Nair","year":"2001","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180912062312_CIS859C7","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/0016-5085(95)90401-8","article-title":"Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus","volume":"109","author":"Perrillo","year":"1995","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180912062312_CIS859C8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2008.02.007","article-title":"ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B","volume":"42","author":"ter Borg","year":"2008","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t20180912062312_CIS859C9","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1440-1746.2008.05391.x","article-title":"Detection of HBV core promoter and precore mutations helps distinguish flares of chronic hepatitis from acute hepatitis B","volume":"23","author":"Kusumoto","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180912062312_CIS859C10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jhep.2009.12.015","article-title":"A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B","volume":"52","author":"Tan","year":"2010","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20180912062312_CIS859C11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3851\/IMP1887","article-title":"Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-\u03b12b: relation to response and HBV genotype","volume":"17","author":"Sonneveld","year":"2012","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180912062312_CIS859C12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/gutjnl-2011-301096","article-title":"Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?","volume":"61","author":"Janssen","year":"2012","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180912062312_CIS859C13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2893.2011.01465.x","article-title":"Hepatitis B surface antigen monitoring and management of chronic hepatitis B","volume":"18","author":"Sonneveld","year":"2011","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20180912062312_CIS859C14","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.23844","article-title":"Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline","volume":"52","author":"Sonneveld","year":"2010","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180912062312_CIS859C15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180912062312_CIS859C16","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1128\/JCM.41.8.3699-3705.2003","article-title":"Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants","volume":"41","author":"Hussain","year":"2003","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180912062312_CIS859C17","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1128\/JCM.38.8.2897-2901.2000","article-title":"Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays","volume":"38","author":"Pas","year":"2000","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180912062312_CIS859C18","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/gut.52.3.416","article-title":"A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy","volume":"52","author":"Yuen","year":"2003","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180912062312_CIS859C19","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1111\/j.1365-2893.2011.01448.x","article-title":"Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B","volume":"18","author":"Zhang","year":"2011","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20180912062312_CIS859C20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2036.2010.04555.x","article-title":"Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?","volume":"33","author":"Rijckborst","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180912062312_CIS859C21","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/j.1440-1746.1998.tb00588.x","article-title":"Association of mutations in the core promoter and precore region of hepatitis virus with fulminant and severe acute hepatitis in Japan","volume":"13","author":"Aritomi","year":"1998","journal-title":"J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180912062312_CIS859C22","first-page":"67","article-title":"Presence of precore and core promoter mutants limits the probability of response to peginterferon in HBeAg-positive chronic hepatitis B","volume-title":"Hepatology","author":"Sonneveld","year":"2012"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/56\/1\/100\/25719562\/cis859.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T14:15:11Z","timestamp":1594736111000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/56\/1\/100\/418781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,5]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,10,5]]},"published-print":{"date-parts":[[2013,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cis859","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,1,1]]},"published":{"date-parts":[[2012,10,5]]}}}